For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| iCBT (Intensive Cognitive Behavioral Therapy) | Patients in this arm will receive transdiagnostic CBT delivered in an intensive format over one weekend. Intensive Cognitive Behavior Therapy (iCBT): Participants randomized to iCBT will receive 16 hours of cognitive behavioral therapy for anxiety over one weekend. The treatment entails psychoeducation, cognitive restructuring and exposure exercises. | 0 | None | 0 | 99 | 0 | 99 | View |
| sCBT (Standard Cognitive Behavioral Therapy) | Patients in this arm will receive transdiagnostic CBT delivered in a standard weekly format for 12 weeks. Standard Cognitive Behavior Therapy (sCBT): Participants randomized to sCBT will receive 16 hours of cognitive behavioral therapy for anxiety weekly over a period of 12 weeks. The treatment entails psychoeducation, cognitive restructuring and exposure exercises. | 0 | None | 0 | 98 | 0 | 98 | View |
| TAU (Treatment as Usual) | Patients in this arm will not receive transdiagnostic CBT but will receive treatment as usual. | 0 | None | 0 | 67 | 0 | 67 | View |